Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

查看全文 作　　者：Kaichao [1]Feng;Yang [2]Liu;Yelei [3]Guo;Jingdan [1]Qiu;Zhiqiang [3]Wu;Hanren [3]Dai;Qingming [1]Yang;Yao [3]Wang;Weidong [1]Han1,3

机构地区：[1]Department of Bio-therapeutic, Chinese PLA General Hospital, Beijing 100853, China;[2]Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, China;[3]Department of Molecular & Immunology, Chinese PLA General Hospital, Beijing 100853, China

出　　处：《Protein & Cell》索引2018年第9卷第10期,共10页

基　　金：We would like to thank all patients who participated in this trial. This study was supported by the grants from the National Natural Science Foundation of China (Grant No. 81230061 to WDH), the Science and Technology Planning Project of Beijing City (No. Z151100003915076 to WDH), the National Key Research and Development Program of China (Nos. 2016YFC1303501 and 2016YFC1303504 to WDH). 关键词：房间癌症治疗受体抗原胰腺胆汁学习

相关文献

参考文献（36）
引证文献（51）
耦合文献（0）

参考文献(36)

引证文献(51)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

参考文献(36)

引证文献(51)

用户提示